Zogenix closes $18 million financing with oxford finance corporation and cit healthcare llc
Zogenix Closes $18 Million Financing with Oxford Finance
Corporation and CIT Healthcare LLC
SAN DIEGO, Calif. - (July 25, 2008):
Zogenix, Inc. (”Zogenix”), a privately held, specialty
pharmaceutical company, announced today it has closed an $18 million secured loan facility with
Oxford Finance Corporation and CIT Healthcare LLC.
Zogenix will use the financing proceeds to continue to prepare for the potential launch of its first
DosePro™, for the treatment of acute migraine. DosePro is Zogenix’s novel
needle-free, pre-filled, single-use delivery technology for subcutaneous drug administration.
Zogenix continues to scale-up its manufacturing capacity and build its sales and marketing
capabilities in preparation for a targeted 2009 launch of sumatriptan
DosePro, subject to the receipt of FDA approval.
“We are very pleased with the support from Oxford and CIT and look forward to working with them
as we continue to grow Zogenix,” said Roger Hawley, Zogenix’s Chief Executive Officer. “Completing our commercial manufacturing readiness, building inventory and building our sales and marketing
infrastructure for our potential first product launch are three of our most important priorities for
2008. We remain on track and on schedule with the commercialization plans for sumatriptan
About Zogenix, Inc.
Zogenix, Inc., with offices in Emeryville and San Diego, CA, is a private, specialty pharmaceutical
company with two proprietary product candidates in late-stage development for the treatment of
central nervous system (CNS) disorders and pain. The company’s lead product candidate, sumatriptan
DosePro™ (previously Intraject®), enables needle-free subcutaneous delivery of
for the treatment of acute migraine and cluster headache. Zogenix submitted a New
Drug Application with the U.S. Food and Drug Administration for sumatriptan
DosePro in December
2007, and it was accepted for filing by the FDA in March 2008. Zogenix’s second product candidate,
ZX002, is a novel, controlled release formulation of hydrocodone
for the treatment of chronic pain.
This product candidate has completed Phase 2 clinical trials, and the company anticipates initiating the Phase 3 clinical program in the second half of 2008. The company also plans to license the
patented DosePro drug-delivery system to other companies. For additional information, visit
Zogenix, DosePro™ and INTRAJECT® are trademarks of Zogenix, Inc.
About Oxford Finance Corporation
Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, is a specialty finance firm
providing senior secured loans to public and private life science companies worldwide. For 20 years,
Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1 billion in
loans, with lines of credit ranging from $500 thousand to $30 million. Oxford is headquartered in
Alexandria, Virginia, with additional offices in California and Massachusetts. For more information,
CIT (NYSE: CIT) is a global commercial finance company that provides financial products and
advisory services to more than one million customers in over 50 countries across 30 industries. A
leader in middle market financing, CIT has more than $70 billion in managed assets and provides financial solutions for more than half of the Fortune 1000. A member of the S&P 500 and Fortune
500, it maintains leading positions in asset-based, cash flow and Small Business Administration
lending, equipment leasing, vendor financing and factoring. The CIT brand platform, Capital
Redefined, articulates its value proposition of providing its customers with the relationship,
intellectual and financial capital to yield infinite possibilities. Founded in 1908, CIT is celebrating its
Department of Veterans Affairs Office of Inspector General Office of Healthcare Inspections Report No. 13-01498-318 Healthcare Inspection An Unexpected Death in a Mental Health Treatment Program VA New Jersey Health Care System Lyons, New Jersey September 17, 2013 Washington, DC 20420 To Report Suspected Wrongdoing in VA Programs and Operations: Telephone:
060-108:Layout 1 25/02/09 18:17 Pagina 94 Produzione scientifica 2007 Produzione scientifica non traslazionale Non traslazionale Produzione Scientifica non traslazionale IF Grezzo ISI 2006 I.F. Norm. Fumagalli F, Molteni R, Racagni G, Riva MA. Stress duringdevelopment: impact on neuroplasticity and relevance topsychopathology. Progress Neurobiol 2007;81:197-217. Fadda P, Bed